Active Ingredient(s): Poractant Alfa
FDA Approved: * November 18, 1999
Pharm Company: * DEY
Category: Neonatal (Infant)

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Curosurf Overview

Pulmonary surfactant is a surface-active complex of phospholipids and proteins formed by type II alveolar cells.[1] The proteins and lipids that make up the surfactant have both hydrophilic and hydrophobic regions. By adsorbing to the air-water interface of alveoli, with hydrophilic head groups in the water and the hydrophobic tails facing towards the air, the main lipid component of surfactant, dipalmitoylphosphatidylcholine (DPPC), reduces surface tension. As a medication, p...

Read more Curosurf Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Curosurf Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Poractant Alfa
  • Suspension: 80mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Curosurf: (2 results)

Sorted by National Drug Code
  • 10122-510 Curosurf 80 mg/ml Endotracheal Suspension by Cornerstone Therapeutics Inc.
  • 63182-180 Curosurf 80 mg/ml Endotracheal Suspension by Chiesi Farmaceutici S.p.a.

Other drugs which contain Poractant Alfa or a similar ingredient: (1 result)